To the Editor:
We would like to thank the interest taken by Flores-Rios et al. As we mentioned in our article,1 our data does not allow us to calculate the risk of stent thrombosis (ST). The estimation of the incidence of confirmed ST in our study, 6/1000 implanted stents, is similar to the accumulated incidence of 0.6% in 3 years in a meta-analysis of 3445 patients2 or that of 0.6% in 15 months of a consecutive series of 12 395 patients.3 Some studies, especially those that include probable and possible thrombosis, show greater incidences. However, the risk of including patients without a true ST is evident.4 Recently it has been proved that this happens even in studies with angiographic confirmation.5
Concerning intrahospital mortality (5.2%), it is similar to that of published studies that, such as ours, include both conventional and drug-eluting stents that vary between 0% to 6%.6-8
With 14 acute ST, 27 sub-acute ST, and only 9 late ST and 8 very late ST, the possibility to correlate the complications of the initial intervention and the chronological type of the thrombosis is limited. In any case, the distribution of ST in the 25 patients with these complications was 10 acute, 11 subacute, and 4 late, which could indicate earlier ST in this subgroup. We did not find ST in any drug-eluting stent implanted inside of a conventional one.